Sign up
Log in
News
CYCCP
9.25
0.00%
0.00
Weekly Report: what happened at CYCCP last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at CYCCP last week (0708-0712)?
Weekly Report · 07/15 09:37
Weekly Report: what happened at CYCCP last week (0701-0705)?
Weekly Report · 07/08 09:37
Weekly Report: what happened at CYCCP last week (0624-0628)?
Weekly Report · 07/01 09:37
CYCLACEL PHARMACEUTICALS: GOT NOTICE FROM EUROPEAN PATENT OFFICE OF INTENTION TO GRANT PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS
Reuters · 06/26 13:20
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Cyclacel Pharmaceuticals, Inc. Has received a notice from the European Patent Office of the intention to grant a patent. The European patent will provide exclusivity until August 2040. The Company is developing innovative medicines based on cancer cell biology. The patent includes claims to novel pharmaceutical compositions of plogosertib.
Barchart · 06/26 08:15
Weekly Report: what happened at CYCCP last week (0617-0621)?
Weekly Report · 06/24 09:39
Weekly Report: what happened at CYCCP last week (0610-0614)?
Weekly Report · 06/17 09:37
Weekly Report: what happened at CYCCP last week (0603-0607)?
Weekly Report · 06/10 09:37
Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action. The data were presented at a poster at the American Society of Clinical Oncology Annual Meeting. Cyclacel Pharmaceuticals is developing a novel treatment for metastatic colorectal cancer.
Benzinga · 06/04 12:27
CYCLACEL PHARMACEUTICALS: FADRACICLIB DEMONSTRATES EFFICACY IN PATIENT-DERIVED COLORECTAL CANCER MODELS AT 2024 ASCO ANNUAL MEETING
Reuters · 06/04 12:06
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma. Data presented at a poster at the American Society of Clinical Oncology Annual Meeting.
Benzinga · 06/03 12:38
Weekly Report: what happened at CYCCP last week (0527-0531)?
Weekly Report · 06/03 09:38
Weekly Report: what happened at CYCCP last week (0520-0524)?
Weekly Report · 05/27 09:39
Weekly Report: what happened at CYCCP last week (0513-0517)?
Weekly Report · 05/20 09:38
Cyclacel Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/14 23:39
Weekly Report: what happened at CYCCP last week (0506-0510)?
Weekly Report · 05/13 09:40
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. Will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The biopharmaceutical company developing innovative medicines based on cancer cell biology. The Company will host a conference call and live webcast on the same day.
Barchart · 05/08 08:15
BRIEF-Cyclacel Pharmaceuticals Inc Files For Resale Of Up To 15.2 Million Shares By The Selling Stockholders
Cyclacel Pharmaceuticals Inc files for resale of up to 15.2 million shares by the selling stockholders. The company says the shares will be sold by the Selling Stockholders. Cyclacel is a maker of drugs for cancer and other diseases. The shares are traded on the New York Stock Exchange.
Reuters · 05/06 21:29
CYCLACEL PHARMACEUTICALS INC FILES FOR RESALE OF UP TO 15.2 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/06 21:28
More
Webull provides a variety of real-time CYCCP stock news. You can receive the latest news about Cyclacel Phar Pr through multiple platforms. This information may help you make smarter investment decisions.
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.